StockIQ.techBioNTech SE (BNTX) Stock Analysis
Free AI-powered analysis and research for BioNTech SE stock
Sector: Healthcare
BNTX snapshot
Data as of 3 Nov 2026 close. Updated daily.
BioNTech SE scores 22/100 on StockIQ's model, which reads as strongly negative signals overall. The price is below its 200-day average and at 19% of its 52-week range, down 15.4% over the past year. Latest reported figures show a profit margin of -63.6%, return on equity of -9.3% and revenue growth of -59.5%.
What is driving the score
- RSI Neutral: +5
- Strong Downtrend: -12
- MACD Bullish: +8
- Declining Revenue (-59.5%): -8
- Unprofitable (-63.6%): -15
- Low Debt (0.02 D/E): +8
- Strong Liquidity (7.85 Current Ratio): +8
- Negative ROE (-9.3%): -10
- Below MA200: -4
- Underperforming (-15.4% over 1 year): -5
- Low Volume (0.5x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full BNTX report
BioNTech SE (BNTX) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze BNTX Now →📰 Latest Update
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
Wed, October 28, 2026 at 4:04 PM UTC 3 min read
BioNTech (BNTX) saw a slight increase in its stock price as Moderna experienced a 4% jump despite a downgrade from William Blair, highlighting the ongoing volatility in the biotech sector. This movement suggests that investors may be reassessing the valuations of mRNA vaccine developers amidst evolving market conditions. As competition remains fierce, BioNTech's performance could be influenced by investor sentiment towards its peers and overall market trends in the biotech industry.